Devyser Diagnostics AB (publ) (DVYSR) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to Divisor Q2 2025 earnings call. I'm Fredrik Dahl and the acting CEO of Divisor and would like to thank you everyone for joining our call today. On the call today we have, in addition to myself, also our CFO Sabina Berlin and our Chief Commercial Officer Thijs Kipling. I will start with a short summary of our quarterly results and then recap our recent activities that have resulted in an improved efficiency overall for the organization. I will then give an update on the recent product launches and present some additional highlights from the quarter before handing over to Sabina for a more detailed review of our financial results in Q2 2025 and then to Thijs for an update on our recent commercial activities. We are turning the company around on a path to profitability. We had another record quarter based on revenue with 67 million second sales representing a growth of around 27% compared to Q2 last year. Gross margins came in at 84%. What we are most proud of is the EBIT that came in at record 5.5 million SEC. This includes a reclassification of non-operational FX impact that Sabina will talk more about and a 1.8 million SEC in one offs related to the reorganization. Our cash position was at the solid 100.4 million SEC. Our reorganization plan that we initiated early this year has now been completed. Along with an improved company-wide cost control process, we have managed to find a much healthier cost structure for the company going forward. Our strong EBIT result improved by 20 million SEK from the previous quarter, and we remain confident that we will reach our financial targets that we previously communicated. of 30% annual organic growth, 80% gross margin, and 20% in EBIT margin by 2026. Our updated strategy is being implemented across the o...